The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma - Leaker, B. R.; Barnes, P. J.; O'Connor, B. J.; Ali, F. Y.; Tam, P.; Neville, J.; Mackenzie, L. F.; MacRury, T. (Clinical and experimental allergy, 2014)
Keywords: Adult; airway hyperresponsiveness; Allergens - administration & dosage; Allergens - immunology; Analysis of Variance; Anti-Asthmatic Agents - pharmacology; Anti-Asthmatic Agents - therapeutic use; asthma; Asthma - diagnosis; Asthma - drug therapy; Asthma - immunology; Asthma - metabolism; Bronchial Provocation Tests; Cross-Over Studies; Cyclohexanols - pharmacology; Cyclohexanols - therapeutic use; Exhalation; Female; Forced Expiratory Volume; Humans; Indans - pharmacology; Indans - therapeutic use; induced sputum; inhaled allergen challenge; Inositol Polyphosphate 5-Phosphatases; Male; Nitric Oxide - metabolism; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphatidylinositols - metabolism; phosphoinositide-3-kinase; Phosphoric Monoester Hydrolases - metabolism; Risk Factors; Severity of Illness Index; SH2-containing inositol-5′-phosphatase 1; Signal Transduction; Sputum; Treatment Outcome; Young Adult; induced sputum; airway hyperresponsiveness; phosphoinositide-3-kinase; asthma; inhaled allergen challenge; SH2-containing inositol-5′-phosphatase 1